Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.47 |
| ▸ | ACHE | P22303 | 4/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
| ▸ | KDM5A | P29375 | 5/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31145938 | 0.85 | KDM5A (0.44) | PARP1ACHECSNK2A1KDM5AFEN1 | |
| SCHEMBL31146052 | 0.83 | PARP1 (0.42) | PARP1ACHECSNK2A1KDM5AFEN1 | |
| SCHEMBL31139875 | 0.75 | PARP1 (0.54) | PARP1ACHECSNK2A1KDM5AFEN1 | |
| SCHEMBL25432233 | 0.75 | PARP1 (0.54) | PARP1ACHECSNK2A1KDM5AFEN1 | |
| SCHEMBL7123033 | 0.75 | PARP1 (0.50) | PARP1ACHEKDM5AFEN1DAO | |
| SCHEMBL31145955 | 0.75 | PDE3B (0.41) | KDM5APOLB | |
| SCHEMBL31145905 | 0.75 | PIM1 (0.47) | PARP1ACHECSNK2A1KDM5AFEN1 | |
| SCHEMBL4394656 | 0.74 | ALDH1A1 (0.48) | PARP1ACHECSNK2A1FEN1POLB | |
| SCHEMBL31146205 | 0.74 | ACHE (0.41) | PARP1ACHECSNK2A1KDM5A | |
| SCHEMBL7116203 | 0.71 | KDM5A (0.49) | PARP1ACHEKDM5AFEN1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688748-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2024206339-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | TNNI3, TNNT2, COQ8A | PARP1 2033/4885ACHE 655/4885CSNK2A1 207/4885 |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, COQ8A | PARP1 2033/4885ACHE 655/4885CSNK2A1 207/4885 |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNT2, TNNI3, TNNC1 | PARP1 3281/4885ACHE 1756/4885CSNK2A1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.